GLP-1 Medication Research

Comprehensive information on GLP-1 medications, their approvals, benefits, and clinical evidence.

Status	Drug	Brand	Approval
US FDA Approved GLP-1 Drugs	Exenatide	Byetta, Bydureon	T2DM
	Liraglutide	Victoza (T2DM), Saxenda (Obesity)	T2DM & Obesity
	Dulaglutide	Trulicity	T2DM
	Lixisenatide	Adlyxin	T2DM
	Semaglutide	Ozempic (T2DM), Rybelsus (oral, T2DM), Wegovy (Obesity)	T2DM & Obesity
	Tirzepatide (dual GLP-1/GIP agonist)	Mounjaro (T2DM), Zepbound (Obesity)	T2DM & Obesity
Not Yet Approved (In Trials or Anticipated)	Cagrilintide / Semaglutide (combo)	N/A	N/A
	Pemvidutide	N/A	N/A
	Survodutide	N/A	N/A
	MariTide	N/A	N/A
	Danuglipron	N/A	N/A
	Mazdutide	N/A	N/A
	Efinopegdutide	N/A	N/A
	Retatrutide (triple agonist: GLP-1/GIP/Glucagon)	N/A	N/A
	Orforglipron	N/A	N/A
	Cagrilintide (solo)	N/A	N/A

Exenatide

StatusUS FDA Approved GLP-1 Drugs

BrandByetta, Bydureon

ApprovalT2DM

Liraglutide

StatusUS FDA Approved GLP-1 Drugs

BrandVictoza (T2DM), Saxenda (Obesity)

ApprovalT2DM & Obesity

Dulaglutide

StatusUS FDA Approved GLP-1 Drugs

BrandTrulicity

ApprovalT2DM

Lixisenatide

StatusUS FDA Approved GLP-1 Drugs

BrandAdlyxin

ApprovalT2DM

Semaglutide

StatusUS FDA Approved GLP-1 Drugs

BrandOzempic (T2DM), Rybelsus (oral, T2DM), Wegovy (Obesity)

ApprovalT2DM & Obesity

Tirzepatide (dual GLP-1/GIP agonist)

StatusUS FDA Approved GLP-1 Drugs

BrandMounjaro (T2DM), Zepbound (Obesity)

ApprovalT2DM & Obesity

Cagrilintide / Semaglutide (combo)